kabutan

ASKA Pharma, 33% Increase in Ordinary Profit, Record High for The First Time in Two Years, Increased Previous Year's Dividend by 5 yen, Plan to Continue the 55 yen Policy This Fiscal Year as Well

Mon May 12, 2025 3:30 pm JST Earnings

4886 ASKA Pharmaceutical Holdings Co.,Ltd. 【J-GAAP】

Earnings Report

ASKA Pharmaceutical Holdings Co.,Ltd. <4886> [TSE Prime] announced its financial results after the market closed on May 12th (15:30). The consolidated ordinary profit for the fiscal year ending March 2025 decreased 21.7% from the previous period to 5.1 billion yen. For the fiscal year ending March 2026, the consolidated ordinary profit is expected to expand to 33.2% to 6.8 billion yenExpected to reach record high profits for the first time in two years. This will be the seventh consecutive term of revenue growth.

At the same time, the company increased the annual dividend for the previous term from 50 yen to 55 yen (compared to 40 yen in the prior term), and has decided to continue with a dividend of 55 yen for the current term as well.

In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit/loss turned to a loss of 0.33 billion yen (compared to a profit of 0.89 billion yen in the same period last year). The operating profit/loss margin drastically worsened from 6.9% in the same period last year to -1.2%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 60,461 5,108 5,232 4,238 150.1 16 May 11, 2023 J-GAAP
Mar, 2024 62,843 6,500 6,522 7,545 266.5 40 May 10, 2024 J-GAAP
Mar, 2025 64,139 5,331 5,107 5,101 180.0 55 May 12, 2025 J-GAAP
YoY +2.1% -18.0% -21.7% -32.4% -32.5%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 63,000 6,700 6,700 5,000 176.3 50 May 10, 2024 J-GAAP
Mar, 2025 Results 64,139 5,331 5,107 5,101 180.0 55 May 12, 2025 J-GAAP
Revision Rate +1.8% -20.4% -23.8% +2.0% +2.1%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 32,371 3,345 3,312 2,560 90.4 25 Nov 5, 2024 J-GAAP
Apr - Sep, 2025 Guidance ー ー ー ー － 27 May 12, 2025 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 62,843 6,500 6,522 7,545 266.5 40 May 10, 2024 J-GAAP
Mar, 2025 64,139 5,331 5,107 5,101 180.0 55 May 12, 2025 J-GAAP
Mar, 2026 Guidance 75,000 6,800 6,800 5,200 183.1 55 May 12, 2025 J-GAAP
YoY +16.9% +27.6% +33.2% +1.9% +1.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 14,019 974 891 1,087 38.4 6.9 May 10, 2024 J-GAAP
Apr - Jun, 2024 16,352 1,758 1,813 1,273 45.0 10.8 Aug 5, 2024 J-GAAP
Jul - Sep, 2024 16,019 1,587 1,499 1,287 45.4 9.9 Nov 5, 2024 J-GAAP
Oct - Dec, 2024 17,555 2,150 2,134 1,538 54.3 12.2 Feb 3, 2025 J-GAAP
Jan - Mar, 2025 14,213 -164 -339 1,003 35.4 -1.2 May 12, 2025 J-GAAP
YoY +1.4% － － -7.7% -7.9%

Related Articles